Published in Support Care Cancer on September 07, 2011
Pharmacological options for the management of refractory cancer pain-what is the evidence? Support Care Cancer (2015) 0.93
Differences between opioids: pharmacological, experimental, clinical and economical perspectives. Br J Clin Pharmacol (2013) 0.88
Switching from morphine to oral methadone in treating cancer pain: what is the equianalgesic dose ratio? J Clin Oncol (1998) 2.29
Strategies to manage the adverse effects of oral morphine: an evidence-based report. J Clin Oncol (2001) 2.25
Establishing "best practices" for opioid rotation: conclusions of an expert panel. J Pain Symptom Manage (2009) 1.96
Opioid rotation: the science and the limitations of the equianalgesic dose table. J Pain Symptom Manage (2009) 1.70
Oxycodone for cancer-related pain: meta-analysis of randomized controlled trials. Arch Intern Med (2006) 1.62
Opioid rotation in patients with cancer pain. A retrospective comparison of dose ratios between methadone, hydromorphone, and morphine. Cancer (1996) 1.33
Dose ratio between morphine and methadone in patients with cancer pain: a retrospective study. Cancer (1998) 1.29
Opioid switching: a systematic and critical review. Cancer Treat Rev (2006) 1.10
No pain relief from morphine? Individual variation in sensitivity to morphine and the need to switch to an alternative opioid in cancer patients. Support Care Cancer (2005) 1.08
Opioid switching and rotation in primary care: implementation and clinical utility. Curr Med Res Opin (2009) 1.03
Frequency, indications, outcomes, and predictive factors of opioid switching in an acute palliative care unit. J Pain Symptom Manage (2009) 1.00
The use of high doses of oxycodone in an acute palliative care unit. Am J Hosp Palliat Care (2010) 0.96
Rapid switching from morphine to methadone in cancer patients with poor response to morphine. J Clin Oncol (1999) 0.88
High dose controlled-release oxycodone in hospice care. J Pain Palliat Care Pharmacother (2006) 0.86
A systematic review of opioid conversion ratios used with methadone for the treatment of pain. Pain Med (2008) 0.85
Oxycodone controlled-release as first-choice therapy for moderate-to-severe cancer pain in Italian patients: results of an open-label, multicentre, observational study. Clin Drug Investig (2008) 0.80
High doses of oxycodone-naloxone combination may provide poor analgesia. Support Care Cancer (2011) 1.65
A five-year retrospective study of the epidemiological characteristics and visual outcomes of patients hospitalized for ocular trauma in a Mediterranean area. BMC Ophthalmol (2008) 1.49
Evaluation of esophageal motility using multichannel intraluminal impedance in healthy children and children with gastroesophageal reflux. J Pediatr Gastroenterol Nutr (2011) 1.49
The use of sublingual fentanyl for breakthrough pain by using doses proportional to opioid basal regimen. Curr Med Res Opin (2013) 1.47
Efficacy of periportal infiltration and intraperitoneal instillation of ropivacaine after laparoscopic surgery in children. J Laparoendosc Adv Surg Tech A (2009) 1.43
CT-guided neurolytic splanchnic nerve block by an anterior approach. J Pain Symptom Manage (2002) 1.39
One-year outcomes with new-generation multifocal intraocular lenses. Ophthalmology (2008) 1.35
Deep sclerectomy versus punch trabeculectomy with or without phacoemulsification: a randomized clinical trial. J Glaucoma (2004) 1.16
Sustained-release oral morphine versus transdermal fentanyl and oral methadone in cancer pain management. Eur J Pain (2008) 1.04
Single nucleotide polymorphisms (SNPs) of pro-inflammatory/anti-inflammatory and thrombotic/fibrinolytic genes in patients with acute ischemic stroke in relation to TOAST subtype. Cytokine (2012) 1.04
Sleep disorders in advanced cancer patients: prevalence and factors associated. Support Care Cancer (2004) 1.03
KPC - 3 Klebsiella pneumoniae ST258 clone infection in postoperative abdominal surgery patients in an intensive care setting: analysis of a case series of 30 patients. BMC Anesthesiol (2013) 1.03
Deep sclerectomy versus trabeculectomy with low-dosage mitomycin C: four-year follow-up. Ophthalmologica (2008) 1.01
Surveillance of multidrug-resistant gram-negative bacilli in a neonatal intensive care unit: prominent role of cross transmission. Am J Infect Control (2007) 1.01
Frequency, indications, outcomes, and predictive factors of opioid switching in an acute palliative care unit. J Pain Symptom Manage (2009) 1.00
Is ranibizumab effective in stopping the loss of vision for choroidal neovascularisation in pathologic myopia? A long-term follow-up study. Br J Ophthalmol (2010) 0.99
Aggressive pharmacological treatment for reversing malignant bowel obstruction. J Pain Symptom Manage (2004) 0.99
Addition of a second opioid may improve opioid response in cancer pain: preliminary data. Support Care Cancer (2004) 0.98
Peritoneal catheter for continuous drainage of ascites in advanced cancer patients. Support Care Cancer (2008) 0.97
Optimization of opioid therapy for preventing incident pain associated with bone metastases. J Pain Symptom Manage (2004) 0.97
Alternative treatments of breakthrough pain in patients receiving spinal analgesics for cancer pain. J Pain Symptom Manage (2005) 0.96
The use of high doses of oxycodone in an acute palliative care unit. Am J Hosp Palliat Care (2010) 0.96
High-dose furosemide and small-volume hypertonic saline solution infusion for the treatment of leg edema in advanced cancer patients. J Pain Symptom Manage (2008) 0.96
A model of acute symptom control unit: Pain Relief and Palliative Care Unit of La Maddalena Cancer Center. Support Care Cancer (2002) 0.96
Opioid escalation in patients with cancer pain: the effect of age. J Pain Symptom Manage (2006) 0.95
Medical treatment for inoperable malignant bowel obstruction: a qualitative systematic review. J Pain Symptom Manage (2007) 0.95
Intrathecal treatment in cancer patients unresponsive to multiple trials of systemic opioids. Clin J Pain (2007) 0.93
Cryptic Leishmania infantum infection in Italian HIV infected patients. BMC Infect Dis (2009) 0.93
Immuno-inflammatory predictors of stroke at follow-up in patients with chronic non-valvular atrial fibrillation (NVAF). Clin Sci (Lond) (2009) 0.92
Controlled sedation for refractory symptoms in dying patients. J Pain Symptom Manage (2008) 0.91
Hyperalgesia: an emerging iatrogenic syndrome. J Pain Symptom Manage (2003) 0.91
Tapentadol in cancer pain management: a prospective open-label study. Curr Med Res Opin (2012) 0.91
E-PTFE (Gore-Tex) implant with or without low-dosage mitomycin-C as an adjuvant in penetrating glaucoma surgery: 2 year randomized clinical trial. Acta Ophthalmol (2007) 0.90
Pegylated liposomal doxorubicin with vinorelbine in metastatic breast carcinoma. A phase I-II clinical investigation. Oncology (2002) 0.90
Safety and effectiveness of intravenous morphine for episodic (breakthrough) pain using a fixed ratio with the oral daily morphine dose. J Pain Symptom Manage (2004) 0.90
Patients' and relatives' perceptions about intravenous and subcutaneous hydration. J Pain Symptom Manage (2005) 0.89
Safety and effectiveness of intravenous morphine for episodic breakthrough pain in patients receiving transdermal buprenorphine. J Pain Symptom Manage (2006) 0.87
Deep sclerectomy versus punch trabeculectomy: effect of low-dosage mitomycin C. Ophthalmologica (2005) 0.87
Peripheral frequency of CD4+ CD28- cells in acute ischemic stroke: relationship with stroke subtype and severity markers. Medicine (Baltimore) (2015) 0.87
Opioid-induced or pain relief-reduced symptoms in advanced cancer patients? Eur J Pain (2006) 0.87
Rapid titration with intravenous morphine for severe cancer pain and immediate oral conversion. Cancer (2002) 0.87
Opioid switching from and to tapentadol extended release in cancer patients: conversion ratio with other opioids. Curr Med Res Opin (2013) 0.87
Pattern and characteristics of advanced cancer patients admitted to hospices in Italy. Support Care Cancer (2012) 0.87
Dosing fentanyl buccal tablet for breakthrough cancer pain: dose titration versus proportional doses. Curr Med Res Opin (2012) 0.86
How do cancer patients receiving palliative care at home die? A descriptive study. J Pain Symptom Manage (2011) 0.86
Incidence of chronic pain in patients with end-stage renal disease on dialysis. J Pain Symptom Manage (2005) 0.86
Breakthrough pain in advanced cancer patients followed at home: a longitudinal study. J Pain Symptom Manage (2009) 0.86
Switching from transdermal drugs: an observational "N of 1" study of fentanyl and buprenorphine. J Pain Symptom Manage (2007) 0.86
Low doses of transdermal fentanyl in opioid-naive patients with cancer pain. Curr Med Res Opin (2010) 0.85
Effects of red blood cell transfusion on anemia-related symptoms in patients with cancer. J Palliat Med (2009) 0.85
Rapid switching between transdermal fentanyl and methadone in cancer patients. J Clin Oncol (2005) 0.84
Emergencies in patients with advanced cancer followed at home. J Pain Symptom Manage (2012) 0.84
Morphine versus oxycodone in pancreatic cancer pain: a randomized controlled study. Clin J Pain (2010) 0.84
Celiac plexus block for pancreatic cancer pain: factors influencing pain, symptoms and quality of life. J Pain Symptom Manage (2003) 0.84
Opioid switching in patients with advanced cancer followed at home. A retrospective analysis. J Pain Symptom Manage (2012) 0.84
An Italian survey on the attitudes in treating breakthrough cancer pain in hospice. Support Care Cancer (2010) 0.84